. Reduction in H/DX [%] of trastuzumab glycan variant peptides (whole sequence), resulting from pepsin and pepsin/type XIII digestion (sequence coverage 81-98% and 87-94% for light and heavy chains, respectively). The relative reduction of the different glycan variants was normalized with the de-glycosylated trastuzumab sample (Degly) data. Depicted are single peptide values (summarized in Table S1) of three targeted (10 min H/DX) experiments with trastuzumab Man5 (light blue), G0F (green), RM (black), ST3 (red), G2F (gray) and ST6 (orange) and Degly (purple). Only minor alterations in H/DX were observed for the analyzed light chain peptides (see inset).
. Uptake difference plot showing D uptake [Da] of alternatively linked trastuzumab sialylation variants (light chain only). Shown are peptides (n=3) obtained by pepsin/type XIII digestion (sequence coverage 83%). The H/DX time course experiment was performed for 0.5 min (pink), 1 min (light blue), 10 min (orange), 30 min (green), 1 h (red), 3 h (purple) and 48 h (black). Table S1. D uptake differences and reduction in H/DX values, as shown in Figure 2 and Figure 3 . Table S2 . Relative FcγR binding of trastuzumab glycan variants (normalized with trastuzumab starting material), as shown in Figure 4 . Table S3 . D uptake differences of trastuzumab G2S2F ST3 vs. ST6, as shown in Figure 5. 
